UNSPSC 51372121: Ethylmorphine hydrochloride

This classification denotes an opioid receptor agonist with the molecular formula C19H23NO3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MFM5450P3T, chemically known as morphinan-6-alpha-ol, 7,8-didehydro-4,5-alpha-epoxy-3-ethoxy-17-methyl-, hydrochloride but more generally known as ethylmorphine hydrochloride, which bears US NIH Compound Identifier 5360692. European Medicines Agency schedules Ethylmorphine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13767MIG.

UNSPSC 51372121 Ethylmorphine hydrochloride is a Commodity code that does not reflect the actual work being solicited under it in recent state and local procurement activity. The three recent opportunities posted under this code involve naloxone procurement, direct-to-manufacturer prescription programs, and multi-source generic pharmaceuticals and OTC products — none of which center on ethylmorphine hydrochloride specifically. The mismatch suggests this code is tagged inconsistently or incorrectly in state and local procurement systems, and the code shows little relevant recent activity aligned with its nominal pharmaceutical product scope.

The issuing bodies across recent activity include a county health department (Seminole County, Florida), a state health and human services commission (Texas HHS Commission), and a multistate cooperative purchasing alliance (Minnesota Multistate Cooperative Purchasing Alliance, serving Minnesota and Oregon participants). Geographic activity spans Florida, Texas, Minnesota, and Oregon. The Seminole County IFB60459723LAS (posted June 30, 2026, due July 26, 2023) seeks 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; the Texas HHS Commission RFI HHS0017013 (posted April 3, 2026) explores direct-to-manufacturer prescription contracting capability; and the MMCAP RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) establishes contracts for generic multi-source pharmaceuticals and OTC products through authorized wholesalers, with pricing weighted at 75 percent and administrative fees at 3 percent on all purchases.